Fennec Pharmaceuticals Inc.
HealthcareNASDAQ:FENC · NASDAQ Capital Market
+$0.15 today
Vol 0.25M · Avg 0.26M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$51.0M of revenue converted into -$8.4M of net income for the selected period. Gross margin is 92.0% and net margin is -17.8%, showing how much revenue survives after costs and taxes. EPS is $-0.31, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.6M -6.1% | $47.5M +123.7% | $21.3M +1284.5% | $1.5M | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $3.8M +18.2% | $3.2M +152.9% | $1.3M +1364.0% | $86.0K | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $40.9M -7.8% | $44.4M +121.8% | $20.0M +1279.8% | $1.4M | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | 91.6% -1.7pp | 93.3% -0.8pp | 94.1% -0.3pp | 94.4% | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $250.0K -18.6% | $307.0K +448.2% | $56.0K -98.4% | $3.5M -29.1% | $5.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $46.9M +13.1% | $41.5M +26.8% | $32.7M +59.5% | $20.5M +67.5% | $12.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $47.2M +12.8% | $41.9M +26.7% | $33.1M +36.6% | $24.2M +40.4% | $17.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $103.0K -87.1% | $800.0K +178.7% | $287.0K +92.6% | $149.0K +831.3% | $16.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$7.5M -255.3% | $4.8M +138.8% | -$12.4M +45.3% | -$22.6M -31.2% | -$17.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -16.7% -26.8pp | 10.1% +68.3pp | -58.2% +1413.3pp | -1471.5% | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$6.3M -356.0% | $2.5M +119.0% | -$13.1M +42.6% | -$22.7M -32.0% | -$17.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -14.2% -19.4pp | 5.2% +66.7pp | -61.4% +1419.9pp | -1481.3% | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $787.0K -50.6% | $1.6M +261.2% | $441.0K +126.2% | $195.0K +261.1% | $54.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $2.1M -48.9% | $4.1M +19.9% | $3.4M +247.0% | $978.0K +676.2% | $126.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$3.3M -29.0% | -$2.5M +14.6% | -$3.0M -206.0% | -$976.0K -693.5% | -$123.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$9.6M -13470.4% | -$71.0K +99.6% | -$16.0M +32.3% | -$23.7M -36.7% | -$17.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -21.6% -21.4pp | -0.1% +75.3pp | -75.5% +1469.4pp | -1544.9% | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $106.0K -71.0% | $365.0K | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$9.7M -2134.2% | -$436.0K +97.3% | -$16.0M +32.3% | -$23.7M -36.7% | -$17.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | -21.8% -20.9pp | -0.9% +74.6pp | -75.5% +1469.4pp | -1544.9% | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -2150.0% | -$0 +97.3% | -$1 +36.8% | -$1 -41.8% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -2150.0% | -$0 +97.3% | -$1 +36.8% | -$1 -41.8% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $28.6M +4.7% | $27.3M +2.7% | $26.6M +1.1% | $26.3M +1.0% | $26.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $28.6M +4.7% | $27.3M +2.7% | $26.6M +1.1% | $26.3M +1.0% | $26.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$284.66M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
$279.42M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$245.51M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$166.70M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
$100.28M
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
$85.08M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does FENC generate?
Fennec Pharmaceuticals Inc. (FENC) reported $44.64M of revenue in fiscal 2025.
Is FENC profitable?
Fennec Pharmaceuticals Inc. (FENC) reported -$9,741,000.00 of net income, with a net margin of -21.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.